Brief: Qurient Announces U.S. FDA Clearance Of Ind Application For Q702, A Novel Cancer Immunotherapy
26/05/2020 14:37
Qurient Co Ltd 115180.KQ :
* QURIENT ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION
FOR
Q702, A NOVEL CANCER IMMUNOTHERAPY
* QURIENT- PHASE 1 CLINICAL STUDY IN PATIENTS WITH ADVANCED
SOLID
TUMOR EXPECTED TO START IN 3Q2020
Source text for Eikon: ID:nBw8Nvd3Pa
Further company coverage: 115180.KQ
Recent news on Qurient
See all newsBrief: Lonza Expands Dual-Payload ADC Technology Offering Through Access To Qurient's CDK7 Inhibitors
Brief: Qurient To Conduct Capital Increase Of 8 Billion Won For Operational Funds
Brief: Qurient Therapeutics Enters Crada With The National Cancer Institute To Collaborate On A Phase 1/2 Clinical Study Of Q901 In Combination With Trop2-Adc
Brief: Qurient Announces Dosing Of First Patient In Q901 Phase 1/2 Clinical Study For The Treatment Of Patients With Solid Tumors
Brief: Qurient Announces Collaboration Agreement With MSD